Black Diamond Therapeutics Inc Stock price
Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.
Key metrics
Black Diamond Therapeutics Inc Stock Analysis
Analyst Opinions
14 Analysts have issued a Black Diamond Therapeutics Inc forecast:
Analyst Opinions
14 Analysts have issued a Black Diamond Therapeutics Inc forecast:
Black Diamond Therapeutics Inc Events
Upcoming Event
Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Black Diamond Therapeutics Inc Stock News
Company Profile
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
| Head office | United States |
| CEO | Dr. Velleca |
| Employees | 21 |
| Founded | 2014 |
| Website | www.blackdiamondtherapeutics.com |


